is great Actually, a Yes. question. that
and on the to the that faster these clients they so successful in earlier as clinic. tools, can us faster LENSai are they BioStrand you them be products need, in development, modules with on better where tell regard that different components really response to give building of our would they and what response emphasis insights succeed to better to is there likely we've with believe or what So in these the been fail more mentioned,
these years X really, that so capabilities were go BioStrand ago, if to we had. not And back
taken specifically LENSai continue that to was and to the turn effort of capabilities. the of also and focus And of that that we're wet vectorization first fundamental all we've But modules, XX still put with and building that all that associated actual by period we those this really these specifically where be recognition off the and into the into We and of integration and the HYFT therapeutic more then antibodies, of pattern completed significant patterns biologic where technology structural research of lab these as during that powered all, a time performing months, capabilities our parts gain of moved those have to LENSai. are those with energy part embedded. insights in
what able And out technology so well the that as but from multiple we're LENSai, with I to back that and to use be able gather subsequently and use be clients remember also utilize the LLMs will not do within LENSai going of management. to aspects and rolled tool insights the be being to enable to for only larger to to these as other tools our again a that resources people foundational to then public encompass laboratory, to also their able to LENSai, data to ability to own
we we've building so have And these in. been components that
repeat clients, repeat mentioned, regard -- into these We we adding drugs from with generation have the they therapeutic capabilities revenue are that feedback. which that the as to, our novel get wet with as you it's arm, clients fantastic. lab these is workflow build And certainly
integrated the loop. into learning that continue capacity, HYFTs of direct more fee-for-service to addition in lab a directly capability. as nature we wet well enriched quite in very as But that both at as we model partnership do work the the type using BioStrand LENSai. robust and in different are as not us of and build clients become pharmaceutical that, have to have We The informed more
LENSai, able industry, started speed again, AI foundation -- in we when insights just meaning do they technology. improve back in and to first can applicability and models those about algorithms, people foundational tap-ins power integrate they're ideal layers not that other is going think direct only and talking that other I can of to other that really also insights complement the of So it they where not but this within LENSai, the these LENSai,
not they're with necessarily competitive these other So technologies.
which what supplying also in leverage collaboration a to technological types it's part people earning, goals of and aspects different they're for partnership and with is enhance of goals major tools both our biological So these to these groups.
the in haven't a to lab we had why specific as in the capacity. that to been the questions initial instance, wet able really who actually partners -- answer wet we lab could they space took not mentioned partners LENSai capabilities using lab. that's we in couldn't had really And previously took complicated answered just wet for on And on, really biological example, programs with the that or be solve
lack so also not asset, far, people tools, have that's but of of these the that successes from moves questions And these I not potential our it as the many things and right, to already in refer to after where into safety doing today insights will the of gained only McHale, AI so to able do clinic. be as things Will helped the future really still build technologies, to further wonderful alluded toxicity the we us the really only having with these these people things wonderful one in like lab, we're the enhancing the developability
as significantly help think I of now, program we're they it's general that And refining one the we're their then focal capabilities simultaneously have in And not LENSai. forward things partnerships. building that emphasizing development are are these partnerships right brought It's at types third largest point us. and through using These we and time, industry same and a foundationally these the of in using really optimizing these demonstrate now lab. can us significant these the problems we These And the tools. that and biological in really just sciences, integration partnerships worth the in for absolutely partnerships additional go for drug tackle us. the of
tell I like probably "We lab can is actually of have told seen silico spot BioStrand's they just back working so worked and the solve worked verbal directly have that's they for validation,and then -- there even for group because this what and, which, getting a in the actually third for on validation, our is just with that And questions. company This hearing hey, AI from larger is for data then companies led this and feedback a group," or incredibly we have pharmaceutical lab we really time with that more us, the data on where much anecdotally, to so comes at that's to they BioStrand, larger, with IPA many perspective."
the a try that this tests us, it. trust part is that now various the turned large various back "where rewarding. what of -- know everyone most out have that's the is the work, we lot group really So AI in first answer validate program, program, work with of us BioStrand to first And really different data," wet "Wow, come out us out And this rewarding there is really we've people skepticism their being said, us, an significantly for resolved. This little external comprehensive meaningful is this. type was saying, at the That is
these LENSai these wet is to these So continuing this continuing pharmaceutical work, balance partnerships, it module really collaborations of but lab with do the companies. to build that
as couple that of push collaborations And also next also technology industry we really to looking over into quarters, those do more believe for the the we're well.
not this change but is drugs. show For how really new discover we're and really the we we get these and meaningful. does furthering validation impact insights, are need these relationships It believe We real. us, to that really develop we additional incredibly to gain only
